SCHEMBL3183299

SCHEMBL3183299

[NH]C(=O)C(CSSc1ccccn1)N1C(=O)CCC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
PKM P14618 2/20 0.40
EHMT2 Q96KQ7 1/20 0.38
EHMT1 Q9H9B1 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
KMT2A Q03164 6/20 0.36
MEN1 O00255 4/20 0.36
MAPT P10636 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 3/20 0.35
HSD17B10 Q99714 1/20 0.34
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44725 0.89 ALDH1A1 (0.50) ALDH1A1PKMEHMT2EHMT1APOBEC3G
SCHEMBL28279888 0.88 ALDH1A1 (0.40) ALDH1A1PKMEHMT2EHMT1APOBEC3G
SCHEMBL1752117 0.80 ALDH1A1 (0.48) ALDH1A1PKMEHMT2EHMT1APOBEC3G
Hydrogen Sulfide SCHEMBL20305480 0.79 ALDH1A1 (0.47) ALDH1A1PKMEHMT2EHMT1APOBEC3G
SCHEMBL3490799 0.78 ALDH1A1 (0.46) ALDH1A1PKMEHMT2EHMT1APOBEC3G
SCHEMBL616908 0.77 ALDH1A1 (0.54) ALDH1A1PKMKMT2AMEN1MAPT
SCHEMBL28630260 0.77 HDAC1 (0.41) ALDH1A1PKMNPC1RAB9ALMNA
SCHEMBL10340280 0.77 HDAC1 (0.47) ALDH1A1PKMKMT2AMAPTHDAC4
SCHEMBL29141153 0.74 ELANE (0.32) ALDH1A1PKM
SCHEMBL9281376 0.74 ALDH1A1 (0.36) ALDH1A1PKMEHMT2EHMT1APOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200190199-A1 ANTIBODY-DRUG CONJUGATES AND USES THEREOF DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2020-06-18 US claimed
US-20050276863-A1 Methods for treatment of aneurysmal tissue MEDTRONIC VASCULAR, INC. (US) 2005-12-15 US claimed
EP-1602925-A2 Methods for treatment of aneurysmal tissue Medtronic Vascular, Inc. (US) 2005-12-07 EP claimed
US-20230414527-A1 FIBRIN PARTICLES AND METHODS OF MAKING THE SAME NORTH CAROLINA STATE UNIVERSITY 2023-12-28 US disclosed
US-11786477-B2 Fibrin particles and methods of making the same NORTH CAROLINA STATE UNIVERSITY (US) 2023-10-17 US disclosed
US-11384150-B2 Antibody-drug conjugates and uses thereof DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2022-07-12 US disclosed
CN-113518923-A Method for the production of lipidated protein structures 默克专利股份公司 2021-10-19 CN disclosed
US-20210169813-A1 FIBRIN PARTICLES AND METHODS OF MAKING THE SAME NORTH CAROLINA STATE UNIVERSITY 2021-06-10 US disclosed
US-20200190199-A1 ANTIBODY-DRUG CONJUGATES AND USES THEREOF DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2020-06-18 US disclosed
WO-2018093864-A1 NANOPARTICLE CONJUGATES AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-05-24 WO disclosed
US-20180133343-A1 NANOPARTICLE CONJUGATES AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-05-17 US disclosed
EP-1602925-B1 System for treatment of aneurysmal tissue MEDTRONIC VASCULAR INC (US) 2008-04-30 EP disclosed
WO-2007122259-A1 FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS. APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-11-01 WO disclosed
US-20060199207-A1 Self-assembly of molecules using combinatorial hybridization APPLIED BIOSYSTEMS, LLC 2006-09-07 US disclosed
US-20060057573-A1 Methods and reagents for detecting target binding by nucleic acid ligands SOMALOGIC, INC (US) 2006-03-16 US disclosed
US-20050282239-A1 Cell-permeable enzyme activation reporter that can be loaded in a high throughput and gentle manner NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-12-22 US disclosed
US-20050276863-A1 Methods for treatment of aneurysmal tissue MEDTRONIC VASCULAR, INC. (US) 2005-12-15 US disclosed
EP-1602925-A2 Methods for treatment of aneurysmal tissue Medtronic Vascular, Inc. (US) 2005-12-07 EP disclosed
EP-1481090-A1 METHODS AND REAGENTS FOR DETECTING TARGET BINDING BY NUCLEIC ACID LIGANDS SomaLogic, Inc. (US) 2004-12-01 EP disclosed
WO-2003070984-A1 METHODS AND REAGENTS FOR DETECTING TARGET BINDING BY NUCLEIC ACID LIGANDS SOMALOGIC, INC. (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133343-A1 NANOPARTICLE CONJUGATES AND USES THEREOF CD47, EPCAM, FCGR2A ALDH1A1 956/4885PKM 4356/4885EHMT2 774/4885
US-11384150-B2 Antibody-drug conjugates and uses thereof EGFR, ERBB2, ERBB3 ALDH1A1 3084/4885PKM 3444/4885EHMT2 3249/4885
US-20200190199-A1 ANTIBODY-DRUG CONJUGATES AND USES THEREOF EGFR, ERBB2, ERBB3 ALDH1A1 3084/4885PKM 3444/4885EHMT2 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.